rhC1INH cuts attack frequency in hereditary angioedema

rhC1INH cuts attack frequency in hereditary angioedema
For patients with hereditary angioedema, weekly administration of recombinant C1INH is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

(HealthDay)—For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

Avner Reshef, M.D., from the Chaim Sheba Medical Center in Tel Hashomer, Israel, and colleagues examined the safety and prophylactic effect of weekly administration of rhC1INH (50 U/kg body weight) in a study involving 25 patients with a history of HAE attacks occurring at least every two weeks. Following a two-week run-in period, patients received rhC1INH administration every week for eight weeks, and were followed for an additional six weeks.

The researchers found that, over the past two years, participants reported attacks at a rate of 0.9/week. During the treatment period, the mean attack rate was 0.4/week. In 13 patients, 30 treatment-emergent mild-to-moderate adverse events were reported. Twenty-five days after the last study drug administration, one patient died from a laryngeal attack. , , and anxiety were reported as the only possible drug-related adverse events in one patient and hypotension was reported in another. No allergic adverse events were reported.

"In summary, weekly administration of 50 U/kg rhC1INH appeared to reduce the frequency of HAE attacks and was generally safe and well tolerated," the authors write. "These encouraging findings warrant further investigation of the clinical value of with rhC1INH."

Several authors disclosed financial ties to the .

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Low-dose duloxetine deemed safe for urinary incontinence

date Jul 27, 2012

(HealthDay) -- Duloxetine appears safe for the routine clinical care of women with stress urinary incontinence (SUI), according to a study published online July 23 in the British Journal of Clinical Pharmacology.

Belimumab deemed safe for long-term lupus treatment

date Jun 19, 2012

(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & ...

Recommended for you

Researchers discover the cause of coeliac disease

date Jun 30, 2015

Professor Ludvig M. Sollid and his colleagues at the University of Oslo have found the cause of coeliac disease. To do so required really going into depth, right down to molecular level. 

Mechanism of T cell self / non-self “education”

date Jun 30, 2015

Researchers at the University of Tokyo have demonstrated that a protease only found in the thymus produces special peptides that promote positive selection of T cells that can detect non-self antigens, a ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.